-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 QGAfXQB17dZHaHsaTkLo4SkRU2EcevSfYaCXjYJVnJaiudeKQrhZKAlRJk+Rna0l
 2VhIV+GdcE9uD7yTnuIzTA==

<SEC-DOCUMENT>0001157523-09-003174.txt : 20090430
<SEC-HEADER>0001157523-09-003174.hdr.sgml : 20090430
<ACCEPTANCE-DATETIME>20090429185036
ACCESSION NUMBER:		0001157523-09-003174
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20090429
ITEM INFORMATION:		Results of Operations and Financial Condition
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20090430
DATE AS OF CHANGE:		20090429

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ANIKA THERAPEUTICS INC
		CENTRAL INDEX KEY:			0000898437
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				043145961
		STATE OF INCORPORATION:			MA
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-14027
		FILM NUMBER:		09780567

	BUSINESS ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801
		BUSINESS PHONE:		6179326616

	MAIL ADDRESS:	
		STREET 1:		236 WEST CUMMINGS PARK
		CITY:			WOBURN
		STATE:			MA
		ZIP:			01801

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ANIKA RESEARCH INC
		DATE OF NAME CHANGE:	19930309
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a5952676.htm
<DESCRIPTION>ANIKA THERAPEUTICS, INC. 8-K
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2008 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 10pt">
    <hr style="width: 100%; text-align: center; height: 1.0 pt; color: #000000">
    <hr style="width: 100%; text-align: center; height: 1.0 pt; color: #000000">


    <p style="text-align: center">
      <br>
      <font style="font-size: 11pt; font-family: Times New Roman">UNITED STATES</font><font style="font-size: 11pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 11pt"></font><font style="font-size: 11pt; font-family: Times New Roman">SECURITIES
      AND EXCHANGE COMMISSION</font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-size: 11pt; font-family: Times New Roman">Washington,
      D.C. 20549</font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-size: 11pt; font-family: Times New Roman">FORM
      8-K</font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-size: 11pt; font-family: Times New Roman">CURRENT
      REPORT</font><font style="font-size: 11pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 11pt"></font><font style="font-size: 11pt; font-family: Times New Roman">PURSUANT
      TO SECTION 13 OR 15(d)</font><font style="font-size: 11pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 11pt"></font><font style="font-size: 11pt; font-family: Times New Roman">OF
      THE SECURITIES EXCHANGE ACT OF 1934</font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-size: 11pt; font-family: Times New Roman">Date
      of Report (Date of earliest event reported): &#160;April 29, 2009</font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-size: 11pt; font-family: Times New Roman">Anika
      Therapeutics, Inc.</font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><i><font style="font-size: 10pt; font-family: Times New Roman">(Exact
      name of registrant as specified in its charter)</font></i><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><font style="font-family: Times New Roman"><b>________________________</b></font><font style="font-family: Times New Roman"><br style="font-family: Times New Roman"></font><br>
    </p>
    <div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="bottom" style="width: 33%; text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Massachusetts
          </p>
        </td>
        <td valign="bottom" style="width: 34%; white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            000-21326
          </p>
        </td>
        <td valign="bottom" style="width: 33%; white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            04-314-5961
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 33%; text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(State or other jurisdiction of<br>incorporation or
            organization)</i>
          </p>
        </td>
        <td valign="top" style="width: 34%; text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>Commission file number</i>
          </p>
        </td>
        <td valign="top" style="width: 33%; text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(I.R.S. Employer<br>Identification No.)</i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            32 Wiggins Avenue, Bedford, MA&#160;&#160;01730
          </p>
        </td>
      </tr>
      <tr>
        <td valign="bottom" style="text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <i>(Address of principal executive offices) (Zip code)</i>
          </p>
        </td>
      </tr>
    </table>
    </div>
    <p style="text-align: center">
      <br>
      <i><font style="font-size: 10pt">Registrant&#8217;s telephone number,
      including area code: &#160;&#160;&#160;</font></i><font style="font-size: 10pt">781-457-9000</font><br><br><br><i><font style="font-size: 10pt">(Former
      name or former address, if changed since last report)</font></i>
    </p>
    <p style="text-align: center">
      <font style="font-family: Times New Roman"><b>________________________</b></font><br><br><br>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Check the
      appropriate box below if the Form 8-K filing is intended to
      simultaneously satisfy the filing obligation of the registrant under any
      of the following provisions:</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      &#160;&#160;<font style="font-size: 10pt; font-family: Times New Roman">Written
      communications pursuant to Rule 425 under the Securities Act (17 CFR
      230.425)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      &#160;&#160;<font style="font-size: 10pt; font-family: Times New Roman">Soliciting
      material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
      240.14a-12)</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      &#160;&#160;<font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
      240.14d-2(b))</font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Arial Unicode MS">&#8414;</font>
      &#160;&#160;<font style="font-size: 10pt; font-family: Times New Roman">Pre-commencement
      communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
      240.13e-4(c))</font><br><br><br>
    </p>
    <hr style="width: 100%; text-align: center; color: #000000; height: 1.0 pt">
    <hr style="width: 100%; text-align: center; color: #000000; height: 1.0 pt">


    <p>

    </p>
    <div style="margin-bottom: 10pt; width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><b>Section
      2--Financial Information</b></font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Item
      2.02.&#160;&#160;&#160;&#160;&#160;Results of Operations and Financial Condition.</font>
    </p>
    <p style="text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">The
      following information, including the exhibit attached hereto, is
      intended to be furnished and shall not be deemed &quot;filed&quot; for purposes of
      Section 18 of the Securities Exchange Act of 1934 (the &quot;Exchange Act&quot;)
      or otherwise subject to the liabilities of that section, nor shall it be
      deemed incorporated by reference in any filing under the Securities Act
      of 1933 or the Exchange Act, except as expressly set forth by specific
      reference in such filing.</font>
    </p>
    <p style="text-align: left">
      <font style="font-size: 10pt; font-family: Times New Roman">On April 29,
      2009, Anika Therapeutics, Inc. issued a press release announcing its
      financial results for the first quarter ended March 31, 2009.&#160;&#160;The full
      text of the press release is furnished as Exhibit 99.1 hereto and is
      incorporated herein by reference.</font>
    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman"><br style="font-family: Times New Roman; font-size: 10pt">
      </font><font style="font-size: 10pt; font-family: Times New Roman"><b>Section
      9--Financial Statements and Exhibits</b></font>
    </p>
    <p>
      <font style="font-size: 10pt; font-family: Times New Roman">Item
      9.01.&#160;&#160;&#160;&#160;&#160;Financial Statements and Exhibits.</font>
    </p>
    <div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px" colspan="2">
          <p style="margin-bottom: 0px; margin-top: 0px">
            (d) Exhibits.
          </p>
        </td>
      </tr>
      <tr>
        <td colspan="2">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 5%; white-space: nowrap; text-align: left; padding-right: 0.0px; padding-left: 0.0px">
          99.1
        </td>
        <td valign="top" style="width: 95%; text-align: left; padding-left: 0.0px">
          Press Release of Anika Therapeutics, Inc. dated April 29, 2009.
        </td>
      </tr>
    </table>
    </div>
    <p>
      <br>
      <br>
      <br>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">[Remainder
      of page left blank intentionally]</font>
    </p>
    <p>

    </p>
    <div style="margin-bottom: 10pt; width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">SIGNATURE</font><br>
    </p>
    <p style="text-align: left">
      Pursuant to the requirements of the Securities Exchange Act of 1934, the
      registrant has duly caused this report to be filed on its behalf by the
      undersigned hereunto duly authorized.
    </p>
    <p style="text-align: center">

    </p>
    <div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px" colspan="3">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Anika Therapeutics, Inc.
          </p>
        </td>
        <td style="width: 16%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td valign="top" style="text-align: left; padding-left: 0.0px" colspan="3">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 16%">

        </td>
      </tr>
      <tr>
        <td valign="top" style="width: 5%; text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Dated:
          </p>
        </td>
        <td valign="top" style="width: 43%; text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            April 29, 2009
          </p>
        </td>
        <td valign="top" style="width: 3%; text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          By:
        </td>
        <td style="width: 3%; border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="top" style="width: 30%; text-align: left; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <p style="margin-bottom: 0px; margin-top: 0px">
            /s/ Kevin W. Quinlan
          </p>
        </td>
        <td style="width: 16%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td valign="top" style="width: 3%; text-align: left; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">
          &#160;
        </td>
        <td valign="top" style="width: 30%; text-align: left; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Kevin W. Quinlan
          </p>
        </td>
        <td style="width: 16%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td valign="top" style="width: 3%; text-align: left; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="width: 30%; text-align: left; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Chief Financial Officer
          </p>
        </td>
        <td style="width: 16%">

        </td>
      </tr>
      <tr>
        <td style="width: 5%">

        </td>
        <td style="width: 43%">

        </td>
        <td style="width: 3%">

        </td>
        <td style="width: 3%">

        </td>
        <td valign="top" style="width: 30%; text-align: left; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td style="width: 16%">

        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <div style="margin-bottom: 10pt; width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <font style="font-size: 10pt; font-family: Times New Roman">Exhibit Index</font>
    </p>
    <p style="text-align: center">

    </p>
    <div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 10pt" cellspacing="0">
      <tr>
        <td valign="top" style="width: 8%; white-space: nowrap; text-align: left; padding-right: 0.0px; padding-left: 0.0px">
          99.1
        </td>
        <td valign="top" style="width: 92%; text-align: left; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            Press Release of Anika Therapeutics, Inc. dated April 29, 2009.
          </p>
        </td>
      </tr>
    </table>
    </div>
  </body>
</html>
<!--<!DOCTYPE html
     PUBLIC "-//W3C//DTD XHTML 1.0 Strict//EN"
     "http://www.w3.org/TR/xhtml1/DTD/xhtml1-strict.dtd">-->
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a5952676_ex991.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
<!--Copyright 2008 Business Wire, a Berkshire Hathaway company.-->
<!--All rights reserved www.businesswire.com-->
  </head>
  <body style="font-family: Times New Roman; font-size: 8pt">
    <p style="text-align: right">
      <b>Exhibit 99.1</b>
    </p>
    <p style="text-align: center">
      <font style="font-size: 12pt; font-family: Times New Roman"><b>Anika
      Therapeutics Reports First Quarter 2009 Results</b></font>
    </p>
    <p style="text-align: center">

    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Revenues
      Rise 8% Led By Strong ORTHOVISC</b></font><b><sup><font style="font-size: 12pt; font-family: Times New Roman">&#174;</font></sup><font style="font-size: 12pt; font-family: Times New Roman">
      Sales Growth</font></b></i>
    </p>
    <p style="text-align: center">
      <i><font style="font-size: 12pt; font-family: Times New Roman"><b>Joint
      Health Revenues Climb 25%</b></font></i>
    </p>
    <p>
      BEDFORD, Mass.--(BUSINESS WIRE)--April 29, 2009--Anika Therapeutics,
      Inc. (Nasdaq: ANIK), a leader in products for tissue protection, healing
      and repair based on hyaluronic acid (&#8220;HA&#8221;) technology, today reported
      financial results for the quarter ending March 31, 2009.
    </p>
    <p>
      <b>Key Highlights</b>
    </p>
    <p>
      During the first quarter, Anika:
    </p>
    <ul>
      <li style="margin-bottom: 10.0px">
        Continued to strengthen its global position in joint health therapies
        with the domestic and international expansion of its flagship joint
        health product, ORTHOVISC<sup>&#174;</sup>;
      </li>
      <li style="margin-bottom: 10.0px">
        Increased both total revenues and product revenues by 8%; and
      </li>
      <li style="margin-bottom: 10.0px">
        Grew joint health revenues by 25%.
      </li>
    </ul>
    <p>
      <b>Revenue</b>
    </p>
    <p>
      Anika&#8217;s product revenue increased by 8% to $8,519,000 for the first
      quarter of 2009, compared with $7,868,000 in the same period last year.
      The increase in product revenue for the quarter was primarily
      attributable to strong domestic and international sales of the Company&#8217;s
      ORTHOVISC product line, as well as gains from MONOVISC sales.
    </p>
    <p>
      Total revenue for the first quarter of 2009 increased 8% to $9,200,000
      from $8,549,000 in the first quarter of 2008.
    </p>
    <p>
      <b>Product Gross Margin</b>
    </p>
    <p>
      Product gross margin for the first quarter of 2009 increased to 62% from
      59% in last year&#8217;s first quarter. The improvement in gross margins was
      due primarily to the growth in joint health product revenue, resulting
      in a more favorable product mix.
    </p>
    <p>
      <b>Other Operating Expenses</b>
    </p>
    <p>
      Research and development expense increased to $2,194,000 compared with
      $1,508,000 in the same period last year, primarily due to the U.S.
      clinical trials for MONOVISC, manufacturing validation activities at the
      Bedford facility, and other development activities in joint health and
      aesthetics. Selling, general and administrative expense was $3,035,000
      compared with $3,069,000 in the same period last year.
    </p>
    <div style="margin-bottom: 10pt; width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>Net Income</b>
    </p>
    <p>
      Net income for the first quarter of 2009 was $523,000, or $0.05 per
      diluted share, compared with $618,000, or $0.05 per diluted share, for
      the same period last year. The decrease in net income in the first
      quarter was due to the current lower interest rate environment.
    </p>
    <p>
      <b>Other</b>
    </p>
    <p>
      Anika&#8217;s cash and cash equivalents at March 31, 2009 were $40,427,000
      compared with $43,194,000 at December 31, 2008. The decrease in cash was
      due to greater working capital needs, and planned capital expenditures,
      as well as a payment for the Company&#8217;s debt obligation related to the
      new facility.
    </p>
    <p>
      <b>Management Commentary</b>
    </p>
    <p>
      &#8220;Anika began the year with another quarter of solid revenue growth,
      driven primarily by our joint health franchise,&#8221; said Charles H.
      Sherwood, Ph.D., Anika&#8217;s president and chief executive officer.
      &#8220;Revenues for joint health were up by 25 percent with strong domestic
      and international contributions.&#8221;
    </p>
    <p>
      &#8220;After having completed the enrollment for our U.S. pivotal clinical
      trial for Anika&#8217;s new single-injection osteoarthritis treatment,
      MONOVISC, and as we did with ORTHOVISC, we initiated a follow-up
      reinjection study for the product,&#8221; said Sherwood. &#8220;In this study, we
      plan to re-treat approximately two-thirds of the initial patients in
      order to demonstrate the safety of repeat injections. We are on-track to
      file for marketing approval for MONOVISC in the U.S. by the end of this
      year.&#8221;
    </p>
    <p>
      &#8220;Looking forward, we plan to continue to capitalize on strong trends in
      joint health as we broaden our presence through an increasing number of
      distributors and an expanding suite of innovative products,&#8221; said
      Sherwood. &#8220;Even in the short term, we believe that patients will turn to
      ORTHOVISC and other HA procedures to postpone expensive and debilitating
      knee replacement surgery during this recessionary period. We continue to
      look forward to generating revenue growth and improved income in 2009.&#8221;
    </p>
    <p>
      <b>Conference Call Information</b>
    </p>
    <p>
      Anika will hold a conference call to discuss its financial results,
      business highlights and outlook on Thursday, April 30, 2009 at 9:00 a.m.
      ET. In addition, the Company will answer questions concerning business
      and financial developments and trends, and other business and financial
      matters affecting the Company, some of the responses to which may
      contain information that has not been previously disclosed.
    </p>
    <p>
      To listen to the conference call, dial 866-788-0542 (International
      callers dial 857-350-1680) and use the passcode 37421541. Please call
      approximately 10 minutes before the starting time and reference Anika
      Therapeutics. In addition, the conference call will be available to
      interested parties through a live audio Internet broadcast at <u>www.anikatherapeutics.com</u>.
      The call will be archived and accessible on the same website shortly
      after the conclusion of the call.
    </p>
    <div style="margin-bottom: 10pt; width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <p>
      <b>About Anika Therapeutics, Inc.</b>
    </p>
    <p>
      Headquartered in Bedford, Mass., Anika Therapeutics, Inc. develops,
      manufactures and commercializes therapeutic products for tissue
      protection, healing and repair. These products are based on hyaluronic
      acid (HA), a naturally occurring, biocompatible polymer found throughout
      the body. Anika&#8217;s products include ORTHOVISC<sup>&#174;</sup>, a
      treatment for osteoarthritis of the knee available internationally and
      marketed in the U.S. by DePuy Mitek; HYVISC<sup>&#174;</sup>, a
      treatment for equine osteoarthritis marketed in the U.S. by Boehringer
      Ingelheim Vetmedica, Inc.; the ELEVESS&#8482; family of aesthetic dermatology
      products for facial wrinkles, scar remediation and lip augmentation;
      AMVISC<sup>&#174;</sup>, AMVISC<sup>&#174;</sup> Plus, STAARVISC&#8482;-II and
      Shellgel&#8482; injectable viscoelastic HA products for ophthalmic surgery;
      INCERT<sup>&#174;</sup>, an HA-based anti-adhesive for surgical
      applications; ORTHOVISC<sup>&#174;</sup> <i>mini</i> a treatment for
      osteoarthritis targeting small joints and available in Europe; MONOVISC&#8482;
      a single-injection osteoarthritis product based on Anika&#8217;s proprietary
      cross-linking technology and also available in Europe and Turkey; and
      next generation products for joint health and aesthetic dermatology
      based on the Company&#8217;s proprietary, chemically modified HA.
    </p>
    <p>
      <i>The statements made in this press release which are not statements of
      historical fact are forward-looking statements within the meaning of
      Section 27A of the Securities Act of 1933 and Section 21E of the
      Securities Exchange Act of 1934, including, without limitation,
      statements that may be identified by words such as &quot;expectations,&quot;
      &quot;remains,&quot; &quot;focus,&quot; &quot;expected,&quot; &quot;prospective,&quot; &quot;expanding,&quot; &quot;building,&quot;
      &quot;continue,&quot; &quot;progress,&quot; &#8220;plan,&#8221; &quot;efforts,&quot; &quot;hope,&quot; &quot;believe,&quot;
      &quot;objectives,&quot; &quot;opportunities,&quot; &quot;will,&quot; &quot;seek,&quot; &#8220;expect&#8221; and other
      expressions which are predictions of or indicate future events and
      trends and which do not constitute historical matters identify
      forward-looking statements.</i> <i>These statements also include: (i)
      the company&#8217;s expectations concerning its MONOVISC product, including
      the U.S. trial and the filing of a PMA (ii) expectations for ORTHOVISC
      growth during the recession (iii) statements concerning leveraging
      investments into new products, (iv) statements concerning revenue and
      income performance in 2009, and (v) statements regarding</i> <i>capitalizing
      on strong trends in joint health as the Company broadens its presence
      through an increasing number of distributors and an expanding suite of
      innovative products .</i> <i>These statements are based upon the current
      beliefs and expectations of the company's management and are subject to
      significant risks, uncertainties and other factors.</i> <i>The company's
      actual results could differ materially from any anticipated future
      results, performance or achievements described in the forward-looking
      statements as a result of a number of factors including: (i) the
      Company&#8217;s ability to license ELEVESS to a new distribution partner on
      terms favorable to the company, if at all; (ii) the company's ability to
      successfully commence and/or complete clinical trials of its products on
      a timely basis or at all, obtain clinical data to support a pre-market
      approval application and/or FDA approval, and/or receive FDA or other
      regulatory approvals of its products, or that such approvals will not be
      obtained in a timely manner or without the need for additional clinical
      trials; (iii) the company's research and product development efforts and
      their relative success, including whether the company has any meaningful
      sales of any new products resulting from such efforts; (vi) the cost
      effectiveness and efficiency of our manufacturing operations and
      production planning; (v) the strength of the economies in which the
      company operates or will be operating, as well as the political
      stability of any of those geographic areas</i> <i>(vi) future
      determinations by the company to allocate resources to products and in
      directions not presently contemplated or (vii) the company&#8217;s ability to
      launch MONOVISC in Europe, if at all.</i> <i>Any delay in receiving any
      regulatory approvals may adversely affect the company's competitive
      position.</i> <i>Even if regulatory approvals are obtained, there is a
      risk that meaningful sales of the products may not be achieved.</i> <i>There
      is also a risk that (i) the company's existing distributors (including
      its distributor in Turkey) or customers will not continue to place
      orders at historical levels or that any of them will seek to modify or
      terminate existing arrangements, (ii) the company's efforts to enter
      into long-term marketing and distribution arrangements, including with
      new international distributors for ORTHOVISC and MONOVISC, will not be
      successful, (iii) new distribution arrangements will not result in
      meaningful sales of the company's products, (iv) the company will be
      unable to achieve performance and sales threshold milestones in its
      distribution agreements, (v) competitive products will adversely impact
      the company's product sales, (vi) the estimated size(s) of the markets
      which the company has targeted its products will fail to be achieved,
      (vii) lack of adequate coverage and reimbursement provided by
      governments and other third party payers for our products and services,
      including non-reimbursement of ORTHOVISC in Turkey, could have a
      material adverse effect on our results of operations, or (viii)
      increased sales of the company's products, including HYVISC, ORTHOVISC ,
      or its ophthalmic products, will not continue or sales will decrease or
      not reach historical sales levels, or even if such increases occur that
      such increases will improve gross margins, any of which may have a
      material adverse effect on the company's business and operations.</i> <i>There
      can be no assurance that the company will license ELEVESS to a new
      distribution partner on terms favorable to the company or at all.</i> <i>Certain
      other factors that might cause the company's actual results to differ
      materially from those in the forward-looking statements include those
      set forth under the headings &quot;Business,&quot; &quot;Risk Factors&quot; and
      &quot;Management's Discussion and Analysis of Financial Condition and Results
      of Operations&quot; in the company's Annual Report on Form 10-K for the year
      ended December 31, 2008, as well as those described in the company's
      other press releases and SEC filings.</i>
    </p>
    <div style="margin-bottom: 10pt; width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 8pt" cellspacing="0">
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="6">
          <b>Anika Therapeutics, Inc. and Subsidiary</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="6">
          <b>Consolidated Statements of Operations</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="6">
          <b>(unaudited)</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td colspan="2">

        </td>
        <td>
          &#160;
        </td>
        <td colspan="2">

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="5">
          <b>Quarter Ended</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt" colspan="5">
          <b>March 31,</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>2009</b>
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>2008</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Product revenue
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          8,519,073
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          7,867,529
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          Licensing, milestone and contract revenue
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          681,251
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          681,250
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Total revenue
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          9,200,324
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          8,548,779
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td colspan="2">

        </td>
        <td>

        </td>
        <td colspan="2">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Operating expenses:
        </td>
        <td colspan="2">

        </td>
        <td>

        </td>
        <td colspan="2">

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Cost of product revenue
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          3,211,666
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          3,216,070
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Research &amp; development
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          2,194,308
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          1,508,340
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 20.0px">
          Selling, general &amp; administrative
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          3,034,982
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          3,068,616
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          Total operating expenses
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          8,440,956
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          7,793,026
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Income from operations
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          759,368
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          755,753
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 20.0px">
          Interest income, net
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          1,440
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          189,406
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Income before income taxes
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          760,808
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          945,159
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 20.0px">
          Provision for income taxes
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          238,088
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          327,601
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 4.0px; padding-left: 0.0px">
          Net income
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          522,720
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          617,558
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Basic net income per share (a):
        </td>
        <td colspan="2">

        </td>
        <td>

        </td>
        <td colspan="2">

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Net income
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          0.05
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          0.05
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Basic weighted average common shares outstanding
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          11,366,545
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          11,225,282
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Diluted net income per share (a):
        </td>
        <td colspan="2">

        </td>
        <td>

        </td>
        <td colspan="2">

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Net income
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          0.05
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          0.05
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Diluted weighted average common shares outstanding
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          11,496,518
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          11,612,720
        </td>
      </tr>
    </table>
    </div>
    <p>
      (a) On January 1, 2009, the company adopted FSP EITF 03-6-1 concerning
      the calculation of earnings per share (&quot;EPS&quot;). The adoption is
      retroactive to all periods presented and reduced three months ended
      March 31, 2008 basic EPS from $0.06 to $0.05.
    </p>
    <div style="margin-bottom: 10pt; width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 8pt" cellspacing="0">
      <tr>
        <td colspan="10">
          &#160;
        </td>
      </tr>
      <tr>
        <td colspan="10">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="10">
          <b>Anika Therapeutics, Inc. and Subsidiary</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="10">
          <b>Consolidated Balance Sheets</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="10">
          <b>(unaudited)</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
        <td colspan="3">

        </td>
        <td>
          &#160;
        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="3">
          <b>March 31,</b>
        </td>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="3">
          <b>December 31,</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>2009</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>2008</b>
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px">
          <b>ASSETS</b>
        </td>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Current assets:
        </td>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Cash and cash equivalents
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          40,426,703
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          43,193,655
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Accounts receivable, net
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          6,483,017
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          5,418,421
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Inventories
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          5,897,332
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          5,519,754
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px" colspan="2">
          Current portion of deferred income taxes
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          1,235,364
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          1,235,364
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 20.0px">
          Prepaid expenses and other
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          858,931
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          463,284
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 40.0px">
          Total current assets
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          54,901,347
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          55,830,478
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Property and equipment, at cost
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          43,481,029
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          42,436,827
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          Less: accumulated depreciation
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          (10,508,898
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: left; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          )
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          (10,190,144
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: left; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          )
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          32,972,131
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          32,246,683
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Long-term deposits and other
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          357,603
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          506,787
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Intangible asset, net
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          921,569
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          936,275
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          Deferred income taxes
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          6,213,980
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          6,300,665
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 4.0px; padding-left: 0.0px">
          Total Assets
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          95,366,630
        </td>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          95,820,888
        </td>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="2">
          <b>LIABILITIES AND STOCKHOLDERS&#8217; EQUITY</b>
        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Accounts payable
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          2,036,244
        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          2,375,340
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Accrued expenses
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          2,612,902
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          2,325,219
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Deferred revenue, current
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          2,732,018
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          2,732,293
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Long-term debt, current
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          1,600,000
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          1,600,000
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Income taxes payable
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          43,544
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          &#8212;
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Other long-term liabilities
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          891,954
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          831,051
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Long-term deferred revenue
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          10,124,996
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          10,800,001
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          Long-term debt
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          14,000,000
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          14,400,000
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 40.0px">
          Total liabilities
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          34,041,658
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          35,063,904
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Stockholders&#8217; equity
        </td>
        <td>

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
        <td>

        </td>
        <td colspan="3">

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Preferred stock
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          &#8212;
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          &#8212;
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Common stock
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          114,359
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          113,776
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 20.0px">
          Additional paid-in-capital
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          42,905,914
        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          42,861,229
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 20.0px">
          Retained earnings
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          18,304,699
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          17,781,979
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 40.0px">
          Total stockholders&#8217; equity
        </td>
        <td>

        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          61,324,972
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td>

        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          60,756,984
        </td>
        <td style="border-bottom: solid black 1.0pt">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 4.0px; padding-left: 0.0px" colspan="2">
          Total Liabilities and Stockholders&#8217; Equity
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          95,366,630
        </td>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          95,820,888
        </td>
        <td style="border-bottom: double black 2.25pt">
          &#160;
        </td>
      </tr>
    </table>
    </div>
    <div style="margin-bottom: 10pt; width: 100%; text-indent: 0pt; margin-right: 0pt; margin-left: 0pt">
      <div>
        <div style="text-align: left">

        </div>
      </div>
      <div style="page-break-after: always">
        <div style="text-align: center">

        </div>
        <div style="text-align: center">
          <hr style="color: black; height: 1.5pt">

        </div>
      </div>
      <div>
        <div style="text-align: right">

        </div>
      </div>
    </div>
    <div style="text-align:left">
    <table style="margin-bottom: 10.0px; font-family: Times New Roman; width: 100%; font-size: 8pt" cellspacing="0">
      <tr>
        <td>

        </td>
        <td colspan="4">
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td colspan="4">
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="4">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Anika Therapeutics, Inc. and Subsidiary</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="4">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Supplemental Financial Data</b>
          </p>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: center; padding-left: 0.0px">
          <p style="margin-bottom: 0px; margin-top: 0px">
            &#160;
          </p>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="4">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>(unaudited)</b>
          </p>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="4">
          <b>Product Gross Margin and Revenue by Product Line</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="4">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Quarter Ended</b>
          </p>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt" colspan="4">
          <b>March 31,</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>2009</b>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>% Ttl</b>
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>2008</b>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>% Ttl</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Joint Health
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $ 5,149,642
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          60%
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $ 4,122,180
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          53%
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Ophthalmic
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          2,645,252
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          31%
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          3,018,671
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          38%
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Veterinary
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          637,335
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          8%
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          700,623
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          9%
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Aesthetics
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          50,094
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          1%
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          3,000
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          0%
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          Other
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          36,750
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          0%
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          23,055
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          0%
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $ 8,519,073
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          100%
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $ 7,867,529
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          100%
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Product gross profit
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $ 5,307,407
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $ 4,651,459
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Product gross margin
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          62%
        </td>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          59%
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="3">
          <b>Product Revenue by Geography</b>
        </td>
        <td>

        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>

        </td>
        <td>
          &#160;
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px" colspan="4">
          <p style="margin-bottom: 0px; margin-top: 0px">
            <b>Quarter Ended</b>
          </p>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt" colspan="4">
          <b>March 31,</b>
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>2009</b>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>% Ttl</b>
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>2008</b>
        </td>
        <td valign="top" style="text-align: center; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          <b>% Ttl</b>
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-left: 0.0px">
          Domestic
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $ 6,135,564
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          72%
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px">
          $ 6,154,111
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px">
          78%
        </td>
      </tr>
      <tr>
        <td valign="top" style="text-align: left; padding-bottom: 2.0px; padding-left: 0.0px">
          International
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          2,383,509
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          28%
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          1,713,418
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: solid black 1.0pt">
          22%
        </td>
      </tr>
      <tr>
        <td>

        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $ 8,519,073
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          100%
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: right; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          $ 7,867,529
        </td>
        <td valign="bottom" style="white-space: nowrap; text-align: center; padding-right: 0.0px; padding-left: 0.0px; border-bottom: double black 2.25pt">
          100%
        </td>
      </tr>
    </table>
    </div>
    <p>

    </p>
    <p>
      CONTACT:<br>Anika Therapeutics, Inc.<br>Charles H. Sherwood, Ph.D., CEO,
      781-457-9000<br>or<br>Kevin W. Quinlan, CFO, 781-457-9000<br>
    </p>
    <p>

    </p>
  </body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
